Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care.

ABSTRACT:

Objective

To determine the feasibility of universal genetic testing of women with newly diagnosed breast cancer, to estimate the incidence of pathogenic gene variants and their impact on patient management, and to evaluate patient and clinician acceptance of universal testing.

Design, setting, participants

Prospective study of women with invasive or high grade in situ breast cancer and unknown germline status discussed at the Parkville Breast Service (Melbourne) multidisciplinary team meeting. Women were recruited to the pilot (12 June 2020 - 22 March 2021) and expansion phases (17 October 2021 - 8 November 2022) of the Mutational Assessment of newly diagnosed breast cancer using Germline and tumour genomICs (MAGIC) study.

Main outcome measures

Germline testing by DNA

SUBMITTER: De Silva DL 

PROVIDER: S-EPMC10952347 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature